Transgenomic, University of Melbourne announce collaboration Transgenomic announced a research agreement with the University of Melbourne to conduct additional clinical validation studies of its Multiplexed ICE COLD-PCRTM technology. The new study will be conducted using DNA isolated from pre-treatment tumor biopsies from patients enrolled in clinical trials. It aims to determine the prevalence and clinical significance of ultra-low frequency mutations that would otherwise go undetected by NGS or Sanger sequencing-based methodologies. In the next phase of the project, Transgenomic expects to conduct further studies with University of Melbourne researchers to validate the use of MX-ICP to accurately detect tumor mutations using blood or plasma. Transgenomic’s MX ICE COLD-PCR technology is exclusively licensed from the Dana-Farber Cancer Institute.